Most boards plan around a single date. The patent expires, competitors arrive, the revenue line falls off a ledge. That model is tidy, it sits in the forecast, and for high-value products it is usually wrong.

A recent analysis on DrugPatentWatch works through the loss-of-exclusivity histories of Revlimid, Humira, Eliquis and Keytruda and finds no cliff anywhere in them. Exclusivity ends in steps. A patent term extension here. A secondary or formulation patent there. A settlement date that matches no patent’s printed expiry. A regulatory exclusivity running on its own clock. Humira’s compound patent expired in December 2016. The first US biosimilar launched in January 2023. A forecast keyed to the compound patent was out by more than six years.

Why the exclusivity timeline beats the patent expiry date

The steps are the interesting part, because they are built rather than granted. Revlimid’s generics entered under volume caps fixed by settlement, not by any patent. Eliquis produced two different entry years for the same drug, years apart, depending only on whether a challenger settled or kept litigating. Merck is building a subcutaneous formulation ahead of Keytruda’s core expiry, and that defensive move has already drawn a fresh infringement fight of its own. Every step traces back to a decision someone took years earlier about what to file, what to extend, what to settle and what to reformulate.

Three things follow, and none of them are specific to pharmaceuticals:

– Model the timeline, not the date. What matters commercially is when competition arrives at full strength, and that number is nowhere on the front page of the patent. The Australian extension record makes the same point from the other side, as I set out in The Pharmaceutical Patent Cliff Has a Timetable — And It’s Public: many molecules are defended by three or more separately extended patents, and those dates are a published calendar of when each competitor becomes vulnerable.

– Treat the settlement date as the operative date, and structure it with that in mind. It usually controls, it can fall before the last patent expires, and it carries a long tail of risk – the lesson of The Reverse Payment You Didn’t Know You Made, where the economics of a deal signed in 2014 were still being unwound more than a decade later.

– Build the second layer while the first still has years to run. Formulation, method-of-use, device and delivery rights are what turn one date into several. The discipline is claiming every commercially viable variant before a competitor carves around you, as When Your Strongest Asset Is What You Leave Off the Label shows.

A step you negotiated is also a step someone can take from you. A listed patent is not a tested one, a settlement can be reopened, and a reformulation can invite a new opponent with a portfolio of its own.

So the useful question for your next board paper is not when the patent expires. It is what your exclusivity timeline actually looks like, which steps you built deliberately, and which ones you are relying on without ever having decided to.

Read the article: The Patent Cliff Is a Myth. What Actually Happens Is a Patent Staircase, and Most Models Miss the Steps, DrugPatentWatch.